The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.

Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M, STARMEN Investigators

Open source

DOI: 10.1016/j.kint.2020.10.014
Published: 2021 Apr
Container: Kidney international
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.kint.2020.10.014,
  title = {The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.},
  author = {Fernández-Juárez G and Rojas-Rivera J and Logt AV and Justino J and Sevillano A and Caravaca-Fontán F and Ávila A and Rabasco C and Cabello V and Varela A and Díez M and Martín-Reyes G and Diezhandino MG and Quintana LF and Agraz I and Gómez-Martino JR and Cao M and Rodríguez-Moreno A and Rivas B and Galeano C and Bonet J and Romera A and Shabaka A and Plaisier E and Espinosa M and Egido J and Segarra A and Lambeau G and Ronco P and Wetzels J and Praga M and STARMEN Investigators},
  year = {2021},
  journal = {Kidney international},
  doi = {10.1016/j.kint.2020.10.014},
  url = {https://doi.org/10.1016/j.kint.2020.10.014}
}

RIS

TY  - JOUR
TI  - The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
AU  - Fernández-Juárez G
AU  - Rojas-Rivera J
AU  - Logt AV
AU  - Justino J
AU  - Sevillano A
AU  - Caravaca-Fontán F
AU  - Ávila A
AU  - Rabasco C
AU  - Cabello V
AU  - Varela A
AU  - Díez M
AU  - Martín-Reyes G
AU  - Diezhandino MG
AU  - Quintana LF
AU  - Agraz I
AU  - Gómez-Martino JR
AU  - Cao M
AU  - Rodríguez-Moreno A
AU  - Rivas B
AU  - Galeano C
AU  - Bonet J
AU  - Romera A
AU  - Shabaka A
AU  - Plaisier E
AU  - Espinosa M
AU  - Egido J
AU  - Segarra A
AU  - Lambeau G
AU  - Ronco P
AU  - Wetzels J
AU  - Praga M
AU  - STARMEN Investigators
PY  - 2021
JO  - Kidney international
DO  - 10.1016/j.kint.2020.10.014
UR  - https://doi.org/10.1016/j.kint.2020.10.014
ER  -

APA

G, F., J, R., AV, L., J, J., A, S., F, C., A, Á., C, R., V, C., A, V., M, D., G, M., MG, D., LF, Q., I, A., JR, G., M, C., A, R., B, R., C, G., J, B., A, R., A, S., E, P., M, E., J, E., A, S., G, L., P, R., J, W., M, P., & Investigators, S. (2021). The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.. Kidney international. https://doi.org/10.1016/j.kint.2020.10.014

Source records

pubmed · retrieved 2026-09-26T11:21:48.702Z